Skip to search boxSkip to navigationSkip to main content

Monitoring for Extra-Intestinal Cancers in IBD

*Corresponding author for this work
Scholary Output:
Contribution to journal
Review article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Multiple studies have demonstrated an increased risk for extra-intestinal cancers in inflammatory bowel disease (IBD) patients, mainly from treatment modalities. Prominent cancers that are related to IBD treatment include the following: lymphoproliferative disorders associated with thiopurine use, hepatosplenic T cell lymphoma primarily in younger male patients on thiopurines and anti-tumor necrosis factor (TNF) agents, non-melanoma skin cancers in patients treated with thiopurines and anti-TNF agents, and melanomas in patients who are on monotherapy with anti-TNF agents. In addition, women with IBD may have higher rates of cervical dysplasia and cervical cancer. The focus of this review is to provide a comprehensive overview on extra-intestinal cancers in IBD patients and how to monitor for these malignancies.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Peer-review

Original language

English (US)

Article number

42

Journal (Volume, Issue Number)

Current Gastroenterology Reports (Volume 17, Issue 11)

Publication milestones

  • Published - 11/22/2015

Publication status

Published - 11/22/2015

ISSN

1522-8037

Publication IDs

  • Scopus: 84941917561
  • PubMed: 26364836

Publication metrics

Metrics

SciVal
FWCI
0.45
SciVal
Author count
2
SciVal
citations
9
SciVal
Paper percentile
66
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
14
Captures
32

Funding Details

Sunanda Kane serves as a consultant to AbbVie and UCB and has received research funding from UCB.
FunderFunding numbers
UCB
-